Myeloma Canada

International Myeloma Foundation (IMF) Launches #MyelomaActionMonth for 2024 March Myeloma Action Month

Retrieved on: 
Tuesday, February 27, 2024
Wall, Research, Doctor of Philosophy, RN, MSN, Courage, Quality of life, Friends, FAAN, Hope, ACTION, Empathy, Education, IMF, Human, Global Video, Bone marrow, Organization, Myeloma Canada, Patient, Family, Disease, Diagnosis, Movement, LIVE, Cryptocurrency

“This March Myeloma Action Month stands as a testament to the collective power of ACTION.

Key Points: 
  • “This March Myeloma Action Month stands as a testament to the collective power of ACTION.
  • Myeloma Action Month isn't just about awareness; it's about empowering ourselves, our loved ones, and the global community to fight back.
  • “This March, let us all take action for Myeloma Action Month and shine a bright light on the collective strength of our global myeloma community.
  • Join the movement and help the IMF spread myeloma awareness on a global scale this 2024 March Myeloma Action Month!

ELREXFIO™ is authorized by Health Canada for adults with relapsed or refractory multiple myeloma in Canada

Retrieved on: 
Tuesday, February 13, 2024
Bone marrow, Health Canada, Multiple myeloma, RRMM, News, Pfizer, B cell, Myeloma Canada, Patient, Disease, Cancer, Pharmaceutical industry

KIRKLAND, QC, Feb. 13, 2024 /CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIO (elranatamab solution for injection).

Key Points: 
  • KIRKLAND, QC, Feb. 13, 2024 /CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIO (elranatamab solution for injection).
  • "The approval of ELREXFIO is good news for patients and their healthcare teams as it offers a new treatment possibility for those living with the disease."
  • Multiple myeloma is the second-most common type of blood cancer, with an estimated 11 Canadians being diagnosed with myeloma every day.iii It is estimated that in 2023, 3,900 Canadians were diagnosed with multiple myeloma and 1,700 Canadians died from the disease.iv
    "Multiple myeloma can be an incredibly challenging cancer to live with and manage," said Martine Elias, Executive Director at Myeloma Canada.
  • This is why it's so important that people living with the disease have access to many and new options even more so when they have relapsed."

Recognizing and Celebrating Outstanding Contributions to the Canadian Cancer Research Community

Retrieved on: 
Monday, November 6, 2023
Women of Outstanding Achievement Photographic Exhibition, FRSC, ISCB Senior Scientist Award, Order of Ontario, FCAN, Medical research, Myeloma Canada, Molecular biology, Multiple myeloma, FRS, Genetics, Jewish General Hospital, Psycho-oncology, RN, Conference, Organization, Federation, Doctor of Philosophy, FRCPC, Doctor of Science, University of Hong Kong, Research, Toronto Metropolitan University, Patient, Senior, McGill University, Princess Margaret Cancer Centre, Professor, University of Toronto, Immune system, Canadian Partnership Against Cancer, University, OC, FCAHS, Palliative care, Distinguished Service to Music Medal, CCRA, Toronto, Breast cancer, University Health Network, University of Manitoba, Ovarian Cancer Research Alliance, Pharmaceutical industry, Nursing, Management, MD, Pharmacology, Cancer

TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

Key Points: 
  • TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
  • Awardees will be honoured at the Canadian Cancer Research Conference, which is taking place in Halifax from November 12 to 14.
  • Initiated in 2011, the CCRA Awards acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community, as well as those who have shown exceptional leadership in patient involvement in cancer research.
  • The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer, and improve patient and survivor outcomes.

FORUS Therapeutics Inc and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for XPOVIO(R)(selinexor)

Retrieved on: 
Wednesday, May 24, 2023
Letter of intent, Nuclear transport, PCPA, Multiple myeloma, XPO1, Myeloma Canada, SINE, Pan-Canadian Pharmaceutical Alliance, Dexamethasone, LOI, Bortezomib, Patient, Master of Science, News, Health insurance, Pharmaceutical industry

Oakville, Ontario--(Newsfile Corp. - May 24, 2023) - FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.

Key Points: 
  • Oakville, Ontario--(Newsfile Corp. - May 24, 2023) - FORUS Therapeutics Inc ("FORUS") and the pan-Canadian Pharmaceutical Alliance ("pCPA") have completed negotiations with a Letter of Intent (LOI) for XPOVIO®(selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
  • This is a significant milestone to ensure that Canadian MM patients have broad and equitable access to XPOVIO," said Kevin Leshuk, President and CEO of FORUS.
  • "This is exciting news for the MM community across Canada," said Martine Elias, MSc, Executive Director, Myeloma Canada.
  • This new treatment regimen provides patients with a unique, effective oral option and meets many of the treatment needs of the myeloma patient community."

International Myeloma Foundation to Host 2023 Global Myeloma Action Network (GMAN) Summit in Frankfurt 

Retrieved on: 
Thursday, May 25, 2023
Czech Republic, NCT, Myeloma Canada, Committee, Hospital, MD, Patient, European, MM, IMF, Disease, National Center for Healthcare Leadership, Executive, Comp 175: A Benefit for Queer Programs and Services in the Pacific Northwest, Protocol, Clinical trial, Service, Multiple myeloma, Policy, Hope, Human, Research, CNN International Europe/Middle East/Africa, Organization, Knowledge, Empowerment, SEE, Canada, SND, International Myeloma Foundation, CTS, Medicine, Gold, University Hospital Heidelberg, Education, Quality of life, Germany, Nursing, Pharmaceutical industry, Management, Risk management, Fine chemical, Renewable energy, Health care, EU, Beer

LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) -- Founded in 2013 by the International Myeloma Foundation (IMF), the Global Myeloma Action Network (GMAN) will hold its Annual Summit in Frankfurt Germany, from June 2-4, 2023.

Key Points: 
  • LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) -- Founded in 2013 by the International Myeloma Foundation (IMF), the Global Myeloma Action Network (GMAN) will hold its Annual Summit in Frankfurt Germany, from June 2-4, 2023.
  • "While multiple myeloma continues to be an incurable disease, we have made remarkable progress in improving patient outcomes and quality of life.
  • “Over the past 10 years, GMAN had a significant increase in attendance of myeloma advocates from different countries.
  • During the 2022 GMAN Summit in Milan, our global network reached 42 myeloma organizations from 39 countries in 5 continents.

FORUS Therapeutics Inc ("FORUS") Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Retrieved on: 
Tuesday, June 7, 2022
MM, Life, Oncology, Caregiver, Adult, Multiple myeloma, Radical behaviorism, Lymphatic system, CEO, Professor, Disease, Plasma cell, Solution, Physician, Sale, Tumor suppressor gene, Therapy, Growth, Bortezomib, Master of Science, Health Canada, Myeloma Canada, Patient, Program, B cell, XPO1, Immune system, Antibody, SINE, Dexamethasone, Department, Princess Margaret Cancer Centre, Bone marrow, Hematology, Cancer, Pharmaceutical industry

This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.

Key Points: 
  • This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.
  • "The FORUS team is very proud to launch XPOVIO in Canada and bring forth a novel and effective addition to existing regimens for the treatment of relapsed or refractory multiple myeloma.
  • XPOVIO is a registered trademark of Karyopharm Therapeutics Inc. and is used by FORUS Therapeutics Inc. under license.
  • FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.

2021 Insights on Multiple Myeloma - Patients by Age Group and Gender - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Oncology, Multiple myeloma, Medical specialties, Medicine, Health care, Myeloma Canada, Monoclonal gammopathy of undetermined significance

The "Global Multiple Myeloma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Multiple Myeloma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The research report, Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2021, provides Multiple Myeloma epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Multiple Myeloma patients, history of the disease at the population level (Multiple Myeloma prevalence, Multiple Myeloma incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Multiple Myeloma patients by age group, gender
    The data from this research will help executives:
    Establish basis for Multiple Myeloma market sizing, assessing market potential, and developing drug forecast models
    Identify Multiple Myeloma patients segments through age groups, gender, and disease sub-types
    Evaluate Multiple Myeloma market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005615/en/

Cancer Patients Support Premiers' Call for Long Overdue Increase to Canada Health Transfer

Retrieved on: 
Tuesday, March 9, 2021
Canada Health Transfer, Myeloma Canada, ICES, Canada, Health care

TORONTO, March 9, 2021 /CNW/ - Cancer patients and their representatives from across Canada today applauded their provincial Premiers for calling on the Federal Government to increase Canada Health Transfer payments from the present 22% to 35% of health spending.

Key Points: 
  • TORONTO, March 9, 2021 /CNW/ - Cancer patients and their representatives from across Canada today applauded their provincial Premiers for calling on the Federal Government to increase Canada Health Transfer payments from the present 22% to 35% of health spending.
  • For the past several years, Federal health transfers have not kept pace with the growth in health spending.
  • What this signifies is a profound decrease in health services for all people living in Canada.
  • However, we must, at the same time, increase funding for already underfunded health conditions, including cancer," stated Martine Elias, Executive Director at Myeloma Canada .

The Myeloma Crowd by The HealthTree Foundation Introduces Community Chapters and Events Platform

Retrieved on: 
Wednesday, March 3, 2021
Multiple myeloma, Myeloma Canada, International Myeloma Foundation, Norwalk, Connecticut

SALT LAKE CITY, March 3, 2021 /PRNewswire/ -- The Myeloma Crowd, a division of The HealthTree Foundation that provides simplified patient education, advocacy and research funding for multiple myeloma, today announced the launch of its new Community Chapters & Events platform.

Key Points: 
  • SALT LAKE CITY, March 3, 2021 /PRNewswire/ -- The Myeloma Crowd, a division of The HealthTree Foundation that provides simplified patient education, advocacy and research funding for multiple myeloma, today announced the launch of its new Community Chapters & Events platform.
  • This platform enables the Myeloma Crowd to build and host events organized by category or chapter, a new way to build and strengthen community among patients.
  • Current event chapters include Fitness for Myeloma, Immunotherapy Treatment, Myeloma Caregivers, Myeloma Financial Coach, Nutrition and Wellness, and Newly Diagnosed Myeloma Patients among others.
  • Jennifer Ahlstrom and her husband Paul founded the HealthTree Foundation and the Myeloma Crowd which provides patient education, advocacy and research funding for multiple myeloma.

HealthTree Foundation Unveils 'Cure in Five' Initiative for Multiple Myeloma Awareness Month

Retrieved on: 
Monday, March 1, 2021
Multiple myeloma, Norwalk, Connecticut, Myeloma Canada, Medicine, Myeloma Foundation

"We're always asking ourselves how we can contribute to faster cures," said Jenny Ahlstrom, myeloma patient and founder of The HealthTree Foundation.

Key Points: 
  • "We're always asking ourselves how we can contribute to faster cures," said Jenny Ahlstrom, myeloma patient and founder of The HealthTree Foundation.
  • Our #CureinFive goal is to identify a myeloma cure, even if for a subset of patients."
  • With March being Multiple Myeloma Awareness Month, the HealthTree Foundation plans to announce a series of new features for its HealthTree CureHub in the coming weeks, aligned with one of the five steps outlined above.
  • Jennifer Ahlstrom and her husband Paul founded the HealthTree Foundation and the Myeloma Crowd which provides patient education, advocacy and research funding for multiple myeloma.